The global chronic gonadotropin Market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is expected to boost the market during the forecast period includes the increasing burden of infertility and hypogonadism around the globe. Moreover, increasing awareness about the human chronic gonadotropin (HCG) among healthcare professionals and patients is a major factor that is expected to accelerate the growth of the market during the forecast period. Furthermore, the continuous R&Ds in gonadotropin extraction and preparation, coupled with favorable initiatives by the government and non-government organizations, are the factors that are anticipated to fuel the demand for HCG globally. With the rising demand for assisted reproductive technologies such as in-vitro fertilization (IVF), the demand for human-derived gonadotropins has increased significantly over the years. HCG hormone plays a vital role after the formation of the embryo. Hence, the usage of HCG in infertility treatment is gaining traction in both men and women. 

According to the Maternal Health Task Force (MHTF), at least 50 million couples globally experience infertility. The growing burden of infertility around the globe is another factor that is anticipated to propel market growth during the forecast period. In addition, HCG is used as the marker in cancer, including choriocarcinoma, seminoma, germ cell tumors, and others. The chorionic gonadotropin hormone is a placental hormone secreted by syncytiotrophoblast cells during pregnancy. These hormones stimulate the corpus luteum to produce progesterone. Moreover, the naturally extracted or recombinant human chorionic gonadotropin hormones are used in the treatment of infertility, male hypogonadism, and many other conditions. The recombinant chorionic gonadotropin products are expected to have significant growth during the forecast period owing to the availability of different strengths and dosages for the individualization of therapy. This, in turn, is expected to offer an opportunity for the growth of the global chronic gonadotropin market.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Type 

o By Technology

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape: Merck & Co., Inc., Ferring BV, and Fresenius Kabi AG, among others. 

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Chronic Gonadotropin Market Report by Segment

By Type

    • Human Chronic Gonadotropin

    • Animal Chronic Gonadotropin

By Technology

    • Female Infertility Treatment

    • Oligospermia Treatment

    • Cryptorchidism Treatment

    • Others

Global Chronic Gonadotropin Market Report by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa